Outcomes of patients with various forms of CID have been dramatically improved with the introduction of anti‐inflammatory and immunomodulatory biologic therapies such as tumor necrosis factor (TNF)‐alpha inhibitors, including infliximab. Here, TNF is linked to combined immunodeficiency.